The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Primary resistance to ICI is common in patients with both RCC and NSCLC, ranging from 35% to 44% and remains unpredictable [1,3].”
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationHapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,022
Radiation effects on antitumor immune responses: current perspectives and challenges
Walle, T., Monge, R. M., Cerwenka, A., Ajona, D., Melero, I., & Lecanda, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017742575 · Cited by 250
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer
Li, R., Ferdinand, J. R., Loudon, K. W., Bowyer, G., Laidlaw, S., Muyas, F., Mamanova, L., Neves, J. B., Bolt, L., Fasouli, E. S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.001 · Cited by 254
Qu, S., Worlikar, T., Felsted, A. E., Ganguly, A., Beems, M. V., Hubbard, R. T., Pepple, A., Kevelin, A. A., Garavaglia, H., Dib, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000200 · Cited by 244
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 245
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 247
Rodriguez-Ruiz, M. E., Rodríguez, I., Garasa, S., Barbés, B., Solórzano, J. L., Perez‐Gracia, J. L., Labiano, S., Sanmamed, M. F., Azpilikueta, A., Bolaños, E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0549 · Cited by 246
Manegold, C., Dingemans, A. C., Gray, J. E., Nakagawa, K., Nicolson, M. C., Peters, S., Reck, M., Wu, Y.-L. L. C., Brustugun, O. T., Crinò, L., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.003 · Cited by 243
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
Lesterhuis, W. J., Bosco, A., Millward, M., SMALL, M. P., Nowak, A. K., & Lake, R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.233 · Cited by 244
Bigot, F., Álvarez, E. C., Baldini, C., Hollebecque, A., Carmona‐Bayonas, A., Postel-Vinay, S. C., Angevin, E., Armand, J., Ribrag, V., Aspeslagh, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.027 · Cited by 246
Buisseret, L., Garaud, S., de Wind, A., den Eynden, G. V., Boisson, A., Solinas, C., Gu‐Trantien, C., Naveaux, C., Lodewyckx, J., Duvillier, H., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1257452 · Cited by 247
Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 241
Cancer immunotherapy: broadening the scope of targetable tumours
van den Bulk, J., Verdegaal, E. M. E., & de Miranda, N. F. C. C. (2018) · Open Biology · doi:10.1098/rsob.180037 · Cited by 244
Diab, A., Tannir, N. M., Bentebibel, S.-E., Hwu, P., Papadimitrakopoulou, V., Haymaker, C., Kluger, H. M., Gettinger, S. N., Sznol, M., Tykodi, S. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1510 · Cited by 237
Self-citationTIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Du, W., Yang, M., Turner, A., Xu, C., Ferris, R. L., Huang, J., Kane, L., & Lu, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030645 · Cited by 242
Escudier, B. J., Motzer, R. J., Sharma, P., Wagstaff, J., Plimack, E. R., Hammers, H. J., Donskov, F. N., Gurney, H., Sosman, J. A., Zalewski, P. G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.037 · Cited by 237
Self-citationTumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Fumet, J.-D., Truntzer, C., Yarchoan, M. M., & Ghiringhelli, F. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.038 · Cited by 242
Braun, D. A., Ishii, Y., Walsh, A. M., Allen, E. M. V., Wu, C. J., Shukla, S. A., & Choueiri, T. K. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3158 · Cited by 236
Self-citationAKT and ERK dual inhibitors: The way forward?
Cao, Z., Liao, Q., Su, M., Huang, K., Jin, J., & Cao, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.025 · Cited by 244
Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01045-x · Cited by 233
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Curry, J. L., Tetzlaff, M. T., Nagarajan, P., Drucker, C. R., Diab, A. K., Hymes, S. R., Duvic, M. A., Hwu, W., Wargo, J. A., Torres-Cabala, C. A., et al. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12858 · Cited by 235
Chen, Y., Zhang, Y. X., Lv, J.-W., Li, Y.-Q., Wang, Y., He, Q.-M., Yang, X.-J., Sun, Y. H., Mao, Y., Yun, J., et al. (2017) · Theranostics · doi:10.7150/thno.21471 · Cited by 234
Lalani, A. A., McGregor, B. A., Albiges, L. K., Choueiri, T. K., Motzer, R. J., Powles, T. B., Wood, C. G., & Bex, A. (2018) · European Urology · doi:10.1016/j.eururo.2018.10.010 · Cited by 235
Self-citationTowards individualized therapy for metastatic renal cell carcinoma
Kotecha, R. R., Motzer, R. J., & Voss, M. H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0209-1 · Cited by 236
Self-citationB7-H3, a checkpoint molecule, as a target for cancer immunotherapy
Yang, S., Wei, W., & Zhao, Q. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.41105 · Cited by 232
Designing nanomedicine for immuno-oncology
Jiang, W., Roemeling, C. A. V., Chen, Y., Qie, Y., Liu, X., Chen, J., & Kim, B. Y. S. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0029 · Cited by 230
Systemic therapy in metastatic renal cell carcinoma
Bedke, J., Gauler, T. C., Grünwald, V., Hegele, A., Herrmann, E., Hinz, S., Janßen, J., Schmitz, S. H., Schostak, M., Tesch, H., et al. (2016) · World Journal of Urology · doi:10.1007/s00345-016-1868-5 · Cited by 230
Self-citationNivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Agrawal, S., Feng, Y., Roy, A., Kollia, G. D., & Lestini, B. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0177-2 · Cited by 232
Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226
Self-citationChemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity
Karin, N., & Razon, H. (2018) · Cytokine · doi:10.1016/j.cyto.2018.02.012 · Cited by 229
Kawazoe, A., Kuwata, T., Kuboki, Y., Shitara, K., Nagatsuma, A. K., Aizawa, M., Yoshino, T., Doi, T., Ohtsu, A., & Ochiai, A. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0631-3 · Cited by 229
Ben‐Ami, E., Barysauskas, C. M., Solomon, S., Tahlil, K., Malley, R., Hohos, M., Polson, K., Loucks, M., Severgnini, M., Patel, T., et al. (2017) · Cancer · doi:10.1002/cncr.30738 · Cited by 231
Self-citationImmunotherapy in Renal Cell Carcinoma: The Future Is Now
Deleuze, A., Saout, J., Dugay, F., Peyronnet, B., Mathieu, R., Verhoest, G., Bensalah, K., Crouzet, L., Laguerre, B., Belaud-Rotureau, M.-A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072532 · Cited by 198
Tanizaki, J., Haratani, K., Hayashi, H., Chiba, Y., Nakamura, Y., Yonesaka, K., Kudo, K., Kaneda, H., Hasegawa, Y., Tanaka, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.030 · Cited by 227
Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
Wilson, D. R., Sen, R., Sunshine, J. C., Pardoll, D. M., Green, J. J., & Kim, Y. J. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.10.013 · Cited by 225
Naing, A., Papadopoulos, K. P., Autio, K. A., Ott, P. A., Patel, M. R., Wong, D. J. L., Falchook, G. S., Pant, S., Whiteside, M., Rasco, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1106 · Cited by 221
Ruan, H., Hu, Q., Wen, D., Chen, Q., Chen, G., Lu, Y., Wang, J., Cheng, H., Lu, W., & Gu, Z. (2019) · Advanced Materials · doi:10.1002/adma.201806957 · Cited by 220
Giorgi, U. D., Procopio, G., Giannarelli, D., Sabbatini, R., Bearz, A., Buti, S., Basso, U., Mitterer, M., Ortega, C., Bidoli, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3661 · Cited by 224
Self-citationGorris, M. A. J., Halilović, A., Rabold, K., van Duffelen, A., Wickramasinghe, I. N. A., Verweij, D. I., Wortel, I. M. N., Textor, J. C., de Vries, I. J. M., & Figdor, C. G. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701262 · Cited by 225
Tada, Y., Togashi, Y., Kotani, D., Kuwata, T., Sato, E., Kawazoe, A., Doi, T., Wada, H., Nishikawa, H., & Shitara, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0403-1 · Cited by 224
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01315-x · Cited by 218
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Li, H., Bullock, K., Gurjao, C., Braun, D., Shukla, S. A., Bossé, D., Lalani, A.-K. A., Gopal, S., Jin, C., Horak, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12361-9 · Cited by 218
Self-citationEfficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0336-8 · Cited by 218
Cella, D. F., Grünwald, V., Nathan, P., Doan, J. F., Dastani, H. B., Taylor, F. C., Bennett, B., DeRosa, M., Berry, S. M., Broglio, K. R., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30125-5 · Cited by 219
Self-citationRecurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Birzu, C., French, P. J., Caccese, M., Cerretti, G., Idbaïh, A., Zagonel, V., & Lombardi, G. (2020) · Cancers · doi:10.3390/cancers13010047 · Cited by 229
Wang, D. Y., Ye, F., Zhao, S., & Johnson, D. B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1344805 · Cited by 220
Nakamura, Y., Tanaka, R., Asami, Y., Teramoto, Y., Imamura, T., Sato, S., Maruyama, H., Fujisawa, Y., Matsuya, T., Fujimoto, M., et al. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13520 · Cited by 219
Hepatocellular carcinoma in the era of immunotherapy
Sim, H., & Knox, J. J. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.10.007 · Cited by 216
Temozolomide-associated hypermutation in gliomas
Choi, S., Yu, Y., Grimmer, M., Wahl, M. T., Chang, S. M., & Costello, J. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy016 · Cited by 221
Sorkhabi, A. D., Khosroshahi, L. M., Sarkesh, A., Mardi, A., Aghebati‐Maleki, A., Maleki, L. A., & Baradaran, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113882 · Cited by 219
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
Gulley, J. L., Madan, R. A., Pachynski, R. K., Mulders, P., Sheikh, N. A., Trager, J. B., & Drake, C. G. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw261 · Cited by 220
Regulatory T cells: a potential target in cancer immunotherapy
Shitara, K., & Nishikawa, H. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13625 · Cited by 218
Yoon, D. H., Osborn, M. J., Tolar, J., & Kim, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020340 · Cited by 218
Noman, M. Z., Hasmim, M., Lequeux, A., Xiao, M., Duhem, C., Chouaı̈b, S., Berchem, G., & Janji, B. (2019) · Cells · doi:10.3390/cells8091083 · Cited by 220
Dizon, D. S., Krilov, L., Cohen, E. E. W., Gangadhar, T. C., Ganz, P. A., Hensing, T. A., Hunger, S. P., Krishnamurthi, S., Lassman, A. B., Markham, M. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8427 · Cited by 218
Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells
Rudqvist, N.-P., Pilones, K. A., Lhuillier, C., Wennerberg, E., Sidhom, J.-W., Emerson, R., Robins, H. S., Schneck, J. P., Formenti, S. C., & Demaria, S. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0134 · Cited by 217
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z., & Yang, X. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s267433 · Cited by 217
Allgäuer, M., Budczies, J., Christopoulos, P., Endris, V., Lier, A., Rempel, E., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.14 · Cited by 212
Grabovska, Y., Mackay, A. G., O’Hare, P., Crosier, S., Finetti, M. A., Schwalbe, E. C., Pickles, J. C., Fairchild, A. R., Avery, A., Cockle, J. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18070-y · Cited by 211
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T. B., Peltola, K. J., de Velasco, G., Burotto, M., Suárez, C., Ghatalia, P., Iacovelli, R., Lam, E. T., Verzoni, E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313906 · Cited by 214
Self-citationLee, J. W., Komar, C. A., Bengsch, F., Graham, K. L., & Beatty, G. L. (2016) · Current Protocols in Pharmacology · doi:10.1002/cpph.2 · Cited by 212
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
Popović, A., Jaffee, E. M., & Zaidi, N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120775 · Cited by 209
Kidney cancer: The next decade
Turajlic, S., Swanton, C., & Boshoff, C. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20181617 · Cited by 213
Ascierto, M. L., McMiller, T. L., Berger, A. E., Danilova, L., Anders, R. A., Netto, G. J., Xu, H., Pritchard, T. S., Fan, J., Cheadle, C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0072 · Cited by 215
Long, G. V., Tykodi, S. S., Schneider, J. G., Garbe, C., Gravis, G., Rashford, M., Agrawal, S., Grigoryeva, E., Bello, A., Roy, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy408 · Cited by 212
Self-citationEfficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Zhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937612 · Cited by 213
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Klil-Drori, A. J., Azoulay, L., & Pollak, M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.120 · Cited by 212
Osta, B. E. E., Hu, F., Sadek, R. A., Chintalapally, R., & Tang, S. C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 208
Kobayashi, T., Iwama, S., Yasuda, Y., Okada, N., Tsunekawa, T., Onoue, T., Takagi, H., Hagiwara, D., Ito, Y., Morishita, Y., et al. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2017-00432 · Cited by 203
Ladomersky, E., Zhai, L., Lenzen, A. C., Lauing, K. L., Qian, J., Scholtens, D. M., Gritsina, G., Sun, X., Liu, Y., Yu, F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3573 · Cited by 208
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 207
Huang, J., Xu, B., Mo, H., Zhang, W., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Yang, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2439 · Cited by 201
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Motzer, R. J., Jonasch, E., Agarwal, N., Alva, A. S., Bagshaw, H. P., Baine, M. J., Beckermann, K. E., Carlo, M. I., Choueiri, T. K., Costello, B. A., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0008 · Cited by 205
Self-citationKoelzer, V. H., Rothschild, S. I., Zihler, D., Wicki, A., Willi, B., Willi, N., Voegeli, M., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0117-1 · Cited by 200
Liu, C., Yu, J., Li, H., Liu, J., Xu, Y., Song, P., Liu, Q., Zhao, H., Xu, J., Maher, V., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.656 · Cited by 202
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman, P. M., Heeke, S., Alix‐Panabières, C., & Pantel, K. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz196 · Cited by 205
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento‐Ribeiro, A. B., García‐Aranda, M., & Rivas, J. D. L. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 202
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Tian, J., Chen, J. H., Chao, S. X., Pelka, K., Giannakis, M., Hess, J. M., Burke, K. P., Jorgji, V., Sindurakar, P., Braverman, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02181-8 · Cited by 205
Role of PD-1 in Immunity and Diseases
Chamoto, K., Al-Habsi, M., & Honjo, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_67 · Cited by 200
Immunomodulatory Activity of VEGF in Cancer
Lapeyre-Prost, A., Terme, M., Pernot, S., Pointet, A., Voron, T., Tartour, É., & Taı̈eb, J. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 203
Manohar, S., Kompotiatis, P., Thongprayoon, C., Cheungpasitporn, W., Herrmann, J., & Herrmann, S. M. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy105 · Cited by 198
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R. A., Lesh, R. W., Ali, U., Kubiak, M. J., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 202
Powles, T. B., Albiges, L. K., Bex, A., Grünwald, V., Porta, C., Procopio, G., Schmidinger, M., Suárez, C., & de Velasco, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.014 · Cited by 202
Self-citationAdra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx680 · Cited by 196
Johnson, D. H., Zobniw, C. M., Trinh, V. A., Ma, J., Bassett, R. L., Abdel‐Wahab, N., Anderson, J. E., Davis, J. E., Joseph, J., Uemura, M. I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0412-0 · Cited by 196
Hu, J., Wang, S., Hou, Y., Chen, Z., Liu, L., Li, R., Li, N., Zhou, L., Yang, Y., Wang, L., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01662-5 · Cited by 207
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
Warner, A. B., Nipp, R. D., Giobbie‐Hurder, A., Johnpulle, R. A. N., Rubin, K. M., Rubinstein, S. M., Flaherty, K. T., Lawrence, D. P., Johnson, D. B., & Sullivan, R. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0450 · Cited by 194
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Cabel, L., Proudhon, C., Romano, E., Girard, N., Lantz, O. J., Stern, M., Pierga, J., & Bidard, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0074-3 · Cited by 197
Sex- and Gender-Based Pharmacological Response to Drugs
Mauvais‐Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., Gouni‐Berthold, I., Heiman, M. L., Kautzky‐Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 203
Sun, L., Zhang, L., Yu, J., Zhang, Y., Pang, X., Ma, C., Shen, M., Ruan, S., Wasan, H. S., & Qiu, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58674-4 · Cited by 192
Molecular approaches for classifying endometrial carcinoma
Piulats, J. M., Guerra, E., Gil-Martín, M., Roman‐Canal, B., Gatius, S., Pamplona, R. S., Velasco, A., Vidal, A., & Matías‐Guiu, X. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.12.015 · Cited by 197
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Vigarios, É., Epstein, J. B., & Sibaud, V. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3629-4 · Cited by 195
Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients
Fendler, A., Bauer, D. E., Busch, J. F., Jung, K., Wulf-Goldenberg, A., Kunz, S., Song, K., Myszczyszyn, A., Elezkurtaj, S., Erguen, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14700-7 · Cited by 197
Immune checkpoint inhibitors and elderly people: A review
Daste, A., Domblides, C., Gross‐Goupil, M., Chakiba, C., Quivy, A., Cochin, V., de Monès, E., Larmonier, N., Soubeyran, P., & Ravaud, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.044 · Cited by 194
Self-citationBiomarkers for immunotherapy in bladder cancer: a moving target
Aggen, D. H., & Drake, C. G. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0299-1 · Cited by 188
Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome
Nielsen, S. M., Rhodes, L. V., Blanco, I., Chung, W. K., Eng, C., Maher, E. R., Richard, S., & Giles, R. H. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.6140 · Cited by 187
Gong, J., Le, T. Q., Massarelli, E., Hendifar, A. E., & Tuli, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0361-7 · Cited by 191
Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000829 · Cited by 186
Gettinger, S. N., Choi, J., Mani, N. L., Sanmamed, M. F., Datar, I. J., Sowell, R., Du, V. Y., Kaftan, E. J., Goldberg, S. B., Dong, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05032-8 · Cited by 188
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Koshkin, V. S., Barata, P. C., Zhang, T., George, D. J., Atkins, M. B., Kelly, W., Vogelzang, N. J., Pal, S. K., Hsu, J., Appleman, L. J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0319-9 · Cited by 185
Pike, L., Bang, A., Mahal, B. A. V., Taylor, A., Krishnan, M. S., Spektor, A., Cagney, D. N., Aizer, A. A., Alexander, B. M., Rahma, O. E., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.09.010 · Cited by 194
Metadata
- Authors
- Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Choueiri, T. K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Tomita, Y., Schutz, F. A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J. S., Xu, L.-A., Waxman, I. M., & Sharma, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Institut Gustave Roussy (FR)
- Beth Israel Deaconess Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Stanford Cancer Institute (US)
- University of Washington (US)
- Vanderbilt University Medical Center (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Fox Chase Cancer Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Westmead Hospital (AU)
- Aarhus University Hospital (DK)
- University of Helsinki (FI)
- Swansea University (GB)
- Essen University Hospital (DE)
- Chiba Cancer Center (JP)
- Niigata University (JP)
- Beneficência Portuguesa de São Paulo (BR)
- BC Cancer Agency (CA)
- Royal Marsden Hospital (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Motzer, Robert J.
- Escudier, Bernard
- McDermott, David F.
- George, Saby
- Hammers, Hans J.
- Tykodi, Scott S.
- Sosman, Jeffrey A.
- Procopio, Giuseppe
- Plimack, Elizabeth R.
- Castellano, Daniel
- Choueiri, Toni K.
- Gurney, Howard
- Donskov, Frede
- Bono, Petri
- Wagstaff, John
- Gauler, Thomas C.
- Ueda, Takeshi
- Tomita, Yoshihiko
- Schutz, Fabio A.
- Kollmannsberger, Christian
- Larkin, James
- Ravaud, Alain
- Sharma, Padmanee
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-05
- Volume
- 373
- Issue
- 19
- Pages
- 1803-1813
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5719487
- OpenAlex
- W2222086386
- Cited by
- 5,807
- References
- 36
- Citations by year
- 2026: 173 · 2025: 255 · 2024: 367 · 2023: 449 · 2022: 535 · 2021: 669 · 2020: 723 · 2019: 669 · 2018: 719 · 2017: 691 · 2016: 511 · 2015: 36
- FWCI
- 515.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab, everolimus, PD-1 inhibitors, mTOR inhibitors, overall survival, objective response rate, progression-free survival, treatment-related adverse events, anti-angiogenic therapy, immune checkpoint inhibitors, mTOR inhibition, fatigue, anemia, previously treated patients
- MeSH terms
- Everolimus, Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Quality of Life, Survival Analysis, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
